As far as CCA is concerned, Metformin significantly suppressed proliferation of RBE and HCCC-9810 CCA cell lines in a dose- and time-dependent manner by targeting the AMPK/mTORC1 pathway24. Here, PRKAA2 is linked to cholangiocarcinoma.